Article ; Online: Prévention de l’allo-immunisation anti-RH1 au premier trimestre de la grossesse: recommandations pour la pratique clinique du Collège National des Gynécologues-Obstétriciens Français.
Gynecologie, obstetrique, fertilite & senologie
2024
Abstract: Objective: To provide recommendations for the prevention of Rh D alloimmunization in the first trimester of pregnancy.: Materials and methods: The quality of evidence of the literature was assessed following the GRADE methodology with questions ... ...
| Title translation | Prevention of Rh D Alloimmunization in the first trimester of the pregnancy: French College of Obstetricians and Gynecologists guidelines for clinical practice. |
|---|---|
| Abstract | Objective: To provide recommendations for the prevention of Rh D alloimmunization in the first trimester of pregnancy. Materials and methods: The quality of evidence of the literature was assessed following the GRADE methodology with questions formulated in the PICO format (Patients, Intervention, Comparison, Outcome) and outcomes defined a priori and classified according to their importance. An extensive bibliographic search was performed on Pubmed, Cochrane, EMBASE, and Google Scholar databases. The quality of evidence was assessed (high, moderate, low, very low) and a recommendation was formulated: (i) strong, (ii) weak, or (iii) no recommendation. The recommendations were reviewed in two rounds with reviewers from the scientific board of the French College of the OB/GYN (Delphi survey) to select the consensus recommendations. Results: The three recommendations from PICO questions reached agreement using the Delphi method. It is recommended not to administer Rh D immunoglobulin before 12 weeks of gestation to reduce the risk of alloimmunization in case of abortion or miscarriage, in RhD negative patients when the genitor is RhD positive or unknown (Weak recommendation. Very low-quality evidence). It is recommended not to administer Rh D immunoglobulin before 12 weeks of gestation to reduce the risk of alloimmunization in cases of bleeding in an ongoing intrauterine pregnancy (Weak recommendation. Very low-quality evidence). The literature data are insufficient in quality and quantity to determine if the injection of Rh D immunoglobulin reduces the risk of alloimmunization in the case of an ectopic pregnancy (No recommendation. Very low-quality evidence). Conclusion: Even though the quality of evidence from the studies is very low, it is recommended not to administer Rh D immunoglobulin in case of abortion, miscarriage or bleeding before 12 weeks of amenorrhea. The quality of evidence was too low to issue a recommendation regarding ectopic pregnancy. |
| Language | French |
| Publishing date | 2024-02-26 |
| Publishing country | France |
| Document type | English Abstract ; Practice Guideline |
| ZDB-ID | 2887456-0 |
| ISSN | 2468-7189 |
| ISSN (online) | 2468-7189 |
| DOI | 10.1016/j.gofs.2024.02.026 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.B 1937: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.